Embolization, Gastric Cancer
Conditions
Brief summary
This is a prospective, open-labelled study to evaluate the efficacy and safety of sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of Initial unresectable gastric cancer.
Interventions
DRUGTransarterial Chemoembolization
Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
Sponsors
Gang Wu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Pathological and imaging diagnosis of gastric adenocarcinoma with initial unresectable R0; 2. Age (18-80 years old) and gender are not limited; 3. No extragastric organ transfer; 4. No serious diseases of the heart, liver, lung, kidney and other organs; 5. Expected survival time \> 3 months; 6. Physical performance status score ECOG ≤1 point; 7. Females of reproductive age must have a negative pregnancy test; or male and female patients must agree to use effective contraception during treatment and within 1 year thereafter.
Exclusion criteria
1. Poor coagulation function, INR\>1.5, or ongoing anticoagulation therapy or known bleeding diseases; 2. WBC \<3000/mm3 or platelet count \<50000/mm3; 3. AST and/or ALT \> 3 times the upper limit of normal; 4. Comorbidities or social environment that can cause subjects to fail to follow the research plan or even endanger patient safety; 5. The patient has other primary tumors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | up to 3 years | Overall survival (OS), defined as the time from study entry (ie, signing the ICF) to death from any cause. For subjects who were alive at the last contact, their overall survival was censored on the date of the last contact. |
| Efficacy evaluation | up to 3 years | Objective response rate (ORR): complete response (CR) + partial response (PR). Evaluation methods: Objective tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Subjects must have measurable tumor lesions at baseline, and the efficacy evaluation criteria are divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD) according to RECIST 1.1 criteria. Complete Remission (CR): All target and non-target lesions disappeared, no new lesions; Partial Remission (PR): Compared with baseline, tumor burden decreased by ≥30%, and non-target lesions did not progress significantly , no new lesions; Stable Disease (SD): neither PR nor PD; Progressive Disease (PD): tumor burden increased by ≥20%, and the absolute value increased by at least 5mm, or non-target lesions progressed, or new lesions (reconfirm progression after at least 6 weeks). |
| Surgical resection rate | up to 3 years | Surgical resection rate: The rate of surgical resection is transformed from those who cannot undergo radical surgical resection and one-stage anastomosis after treatment. |
| PFS | up to 3 years | Progression-free survival（PFS） is defined as the time between the date of randomization and any documented tumor progression or death from any cause. |
Contacts
Primary ContactGang Wu, MD
Outcome results
None listed